Abstract
The proper diagnosis of hyponatremia is a vital component of the perioperative care of liver transplant patients, as hyponatremia is common among patients with end-stage liver disease. The general recommendation for the treatment of chronic hyponatremia is to limit the speed of correction. Unfortunately, the peri-transplantation period is often punctuated by large fluctuations in serum sodium concentration, which increases the risk of neurologic complications and osmotic demyelination syndrome. Consequently, the therapeutic goals and management strategies for hyponatremia vary greatly between the pre-transplantation, intraoperative, and post-transplantation periods. In this chapter, the definition, prognosis, pathophysiology, and treatment of hyponatremia in patients with cirrhosis are reviewed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119:S30–5. https://doi.org/10.1016/j.amjmed.2006.05.005.
Leung AA, McAlister FA, Rogers SO Jr, Pazo V, Wright A, Bates DW. Preoperative hyponatremia and perioperative complications. Arch Intern Med. 2012;172:1474–81. https://doi.org/10.1001/archinternmed.2012.3992.
Angeli P, Wong F, Watson H, Gines P, Investigators C. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006;44:1535–42. https://doi.org/10.1002/hep.21412.
Guevara M, Baccaro ME, Torre A, Gomez-Anson B, Rios J, Torres F, et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol. 2009;104:1382–9. https://doi.org/10.1038/ajg.2009.293.
Gines P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology. 2008;48:1002–10. https://doi.org/10.1002/hep.22418.
Amodio P, Del Piccolo F, Petteno E, Mapelli D, Angeli P, Iemmolo R, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol. 2001;35:37–45.
Sola E, Watson H, Graupera I, Turon F, Barreto R, Rodriguez E, et al. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol. 2012;57:1199–206. https://doi.org/10.1016/j.jhep.2012.07.020.
Saab S, Ibrahim AB, Shpaner A, Younossi ZM, Lee C, Durazo F, et al. MELD fails to measure quality of life in liver transplant candidates. Liver Transpl. 2005;11:218–23. https://doi.org/10.1002/lt.20345.
Sterns RH, Silver SM. Brain volume regulation in response to hypo-osmolality and its correction. Am J Med. 2006;119:S12–6. https://doi.org/10.1016/j.amjmed.2006.05.003.
Cordoba J, Gottstein J, Blei AT. Chronic hyponatremia exacerbates ammonia-induced brain edema in rats after portacaval anastomosis. J Hepatol. 1998;29:589–94.
Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004;40:802–10. https://doi.org/10.1002/hep.20405.
Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005;41:32–9. https://doi.org/10.1002/hep.20517.
Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005;11:336–43. https://doi.org/10.1002/lt.20329.
Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–26. https://doi.org/10.1056/NEJMoa0801209.
Londono MC, Cardenas A, Guevara M, Quinto L, de Las Heras D, Navasa M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut. 2007;56:1283–90. https://doi.org/10.1136/gut.2006.102764.
Cardenas A, Sola E, Rodriguez E, Barreto R, Graupera I, Pavesi M, et al. Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANONIC study. Crit Care. 2014;18:700. https://doi.org/10.1186/s13054-014-0700-0.
Machicao VI. Model for end-stage liver disease-sodium score: the evolution in the prioritization of liver transplantation. Clin Liver Dis. 2017;21:275–87. https://doi.org/10.1016/j.cld.2016.12.014.
Fisher RA, Heuman DM, Harper AM, Behnke MK, Smith AD, Russo MW, et al. Region 11 MELD Na exception prospective study. Ann Hepatol. 2012;11:62–7.
Sharma P, Schaubel DE, Goodrich NP, Merion RM. Serum sodium and survival benefit of liver transplantation. Liver Transpl. 2015;21:308–13. https://doi.org/10.1002/lt.24063.
Leise MD, Yun BC, Larson JJ, Benson JT, Yang JD, Therneau TM, et al. Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation. Liver Transpl. 2014;20:687–97. https://doi.org/10.1002/lt.23860.
Wang P, Huang G, Tam N, Wu C, Fu S, Hughes BP, et al. Influence of preoperative sodium concentration on outcome of patients with hepatitis B virus cirrhosis after liver transplantation. Eur J Gastroenterol Hepatol. 2016;28:1210–5. https://doi.org/10.1097/MEG.0000000000000690.
Londono MC, Guevara M, Rimola A, Navasa M, Taura P, Mas A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology. 2006;130:1135–43. https://doi.org/10.1053/j.gastro.2006.02.017.
Dawwas MF, Lewsey JD, Neuberger JM, Gimson AE. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl. 2007;13:1115–24. https://doi.org/10.1002/lt.21154.
Urso C, Brucculeri S, Caimi G. Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions. J Clin Pharm Ther. 2015;40:376–85. https://doi.org/10.1111/jcpt.12279.
Asbert M, Gines A, Gines P, Jimenez W, Claria J, Salo J, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology. 1993;104:1485–91.
Bernardi M, Ricci CS, Santi L. Hyponatremia in patients with cirrhosis of the liver. J Clin Med. 2014;4:85–101. https://doi.org/10.3390/jcm4010085.
Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170:G1–47. https://doi.org/10.1530/EJE-13-1020.
Sterns RH, Hix JK, Silver SM. Management of hyponatremia in the ICU. Chest. 2013;144:672–9. https://doi.org/10.1378/chest.12-2600.
Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol. 2009;29:282–99. https://doi.org/10.1016/j.semnephrol.2009.03.002.
Sterns RH, Hix JK, Silver S. Treating profound hyponatremia: a strategy for controlled correction. Am J Kidney Dis. 2010;56:774–9. https://doi.org/10.1053/j.ajkd.2010.04.020.
Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120:S1–21. https://doi.org/10.1016/j.amjmed.2007.09.001.
Hoorn EJ, Zietse R. Diagnosis and treatment of hyponatremia: compilation of the guidelines. J Am Soc Nephrol. 2017;28:1340–9. https://doi.org/10.1681/ASN.2016101139.
Norenberg MD. Central pontine myelinolysis: historical and mechanistic considerations. Metab Brain Dis. 2010;25:97–106. https://doi.org/10.1007/s11011-010-9175-0.
Gankam Kengne F, Nicaise C, Soupart A, Boom A, Schiettecatte J, Pochet R, et al. Astrocytes are an early target in osmotic demyelination syndrome. J Am Soc Nephrol. 2011;22:1834–45. https://doi.org/10.1681/ASN.2010111127.
Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126:S1–42. https://doi.org/10.1016/j.amjmed.2013.07.006.
Yun BC, Kim WR, Benson JT, Biggins SW, Therneau TM, Kremers WK, et al. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology. 2009;49:1610–5. https://doi.org/10.1002/hep.22846.
Crivellin C, Cagnin A, Manara R, Boccagni P, Cillo U, Feltracco P, et al. Risk factors for central pontine and extrapontine myelinolysis after liver transplantation: a single-center study. Transplantation. 2015;99:1257–64. https://doi.org/10.1097/TP.0000000000000496.
Louis G, Megarbane B, Lavoue S, Lassalle V, Argaud L, Poussel JF, et al. Long-term outcome of patients hospitalized in intensive care units with central or extrapontine myelinolysis. Crit Care Med. 2012;40:970–2. https://doi.org/10.1097/CCM.0b013e318236f152.
Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716–21. https://doi.org/10.1053/jhep.2002.31250.
Lee J, Kim DK, Lee JW, Oh KH, Oh YK, Na KY, et al. Rapid correction rate of hyponatremia as an independent risk factor for neurological complication following liver transplantation. Tohoku J Exp Med. 2013;229:97–105.
Hix JK, Silver S, Sterns RH. Diuretic-associated hyponatremia. Semin Nephrol. 2011;31:553–66. https://doi.org/10.1016/j.semnephrol.2011.09.010.
Rose BD, Post TW. Clinical physiology of acid-base and electrolyte disorders. 5th ed. Medical Publishing Division: McGraw-Hill; 2001.
John S, Thuluvath PJ. Hyponatremia in cirrhosis: pathophysiology and management. World J Gastroenterol. 2015;21:3197–205. https://doi.org/10.3748/wjg.v21.i11.3197.
European Association for the Study of the L. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417. https://doi.org/10.1016/j.jhep.2010.05.004.
Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57:1651–3. https://doi.org/10.1002/hep.26359.
Rose BD. New approach to disturbances in the plasma sodium concentration. Am J Med. 1986;81:1033–40.
Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112. https://doi.org/10.1056/NEJMoa065181.
Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M, et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut. 2012;61:108–16. https://doi.org/10.1136/gutjnl-2011-300157.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–18. https://doi.org/10.1056/NEJMoa1205511.
Dahl E, Gluud LL, Kimer N, Krag A. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Aliment Pharmacol Ther. 2012;36:619–26. https://doi.org/10.1111/apt.12025.
Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U. Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. Am J Kidney Dis. 2010;56:325–37. https://doi.org/10.1053/j.ajkd.2010.01.013.
O'Leary JG, Davis GL. Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transpl. 2009;15:1325–9. https://doi.org/10.1002/lt.21836.
Abbasoglu O, Goldstein RM, Vodapally MS, Jennings LW, Levy MF, Husberg BS, et al. Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis. Clin Transpl. 1998;12:263–9.
Miller PD, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA. 1980;243:2513–5.
Gadano A, Moreau R, Pessione F, Trombino C, Giuily N, Sinnassamy P, et al. Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis. J Hepatol. 2000;32:38–42.
Brandman D, Biggins SW, Hameed B, Roberts JP, Terrault NA. Pretransplant severe hepatic encephalopathy, peritransplant sodium and post-liver transplantation morbidity and mortality. Liver Int. 2012;32:158–64. https://doi.org/10.1111/j.1478-3231.2011.02618.x.
Lee EM, Kang JK, Yun SC, Kim KH, Kim SJ, Hwang KS, et al. Risk factors for central pontine and extrapontine myelinolysis following orthotopic liver transplantation. Eur Neurol. 2009;62:362–8. https://doi.org/10.1159/000242426.
Morard I, Gasche Y, Kneteman M, Toso C, Mentha A, Meeberg G, et al. Identifying risk factors for central pontine and extrapontine myelinolysis after liver transplantation: a case-control study. Neurocrit Care. 2014;20:287–95. https://doi.org/10.1007/s12028-013-9928-9.
Wszolek ZK, McComb RD, Pfeiffer RF, Steg RE, Wood RP, Shaw BW Jr, et al. Pontine and extrapontine myelinolysis following liver transplantation. Relationship to serum sodium. Transplantation. 1989;48:1006–12.
Hudcova J, Ruthazer R, Bonney I, Schumann R. Sodium homeostasis during liver transplantation and correlation with outcomes. Anesth Analg. 2014;119:1420–8. https://doi.org/10.1213/ANE.0000000000000415.
McCormick PA, Mistry P, Kaye G, Burroughs AK, McIntyre N. Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. Gut. 1990;31:204–7.
Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581–9. https://doi.org/10.1056/NEJM200005253422107.
Larner AJ, Vickers CR, Adu D, Buckels JA, Elias E, Neuberger J. Correction of severe hyponatraemia by continuous arteriovenous haemofiltration before liver transplantation. BMJ. 1988;297:1514–5.
Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology. 2004;39:464–70. https://doi.org/10.1002/hep.20056.
Hackworth WA, Heuman DM, Sanyal AJ, Fisher RA, Sterling RK, Luketic VA, et al. Effect of hyponatraemia on outcomes following orthotopic liver transplantation. Liver Int. 2009;29:1071–7. https://doi.org/10.1111/j.1478-3231.2009.01982.x.
Langer T, Ferrari M, Zazzeron L, Gattinoni L, Caironi P. Effects of intravenous solutions on acid-base equilibrium: from crystalloids to colloids and blood components. Anaesthesiol Intensive Ther. 2014;46:350–60. https://doi.org/10.5603/AIT.2014.0059.
Ghaffaripour S, Jannatmakan F, Firoozifar M. Practical protocol for management of severe hyponatremia in patients undergoing liver transplant surgery. Prog Transplant. 2015;25:106. https://doi.org/10.7182/pit2015186.
Atchison SR, Rettke SR, Fromme GA, Janossy TA, Kunkel SE, Williamson KR, et al. Plasma glucose concentrations during liver transplantation. Mayo Clin Proc. 1989;64:241–5.
MacMillan TE, Tang T, Cavalcanti RB. Desmopressin to prevent rapid sodium correction in severe hyponatremia: a systematic review. Am J Med. 2015;128:1362 e15–24. https://doi.org/10.1016/j.amjmed.2015.04.040.
Brinson EL, Yu JS, Liu LL, Bokoch MP. Desmopressin reverses overly rapid serum sodium correction in a hyponatremic patient undergoing living donor liver transplantation: a case report. A A Pract. 2018;11(3):82–4.
Bonham CA, Dominguez EA, Fukui MB, Paterson DL, Pankey GA, Wagener MM, et al. Central nervous system lesions in liver transplant recipients: prospective assessment of indications for biopsy and implications for management. Transplantation. 1998;66:1596–604.
Rafat C, Schortgen F, Gaudry S, Bertrand F, Miguel-Montanes R, Labbe V, et al. Use of desmopressin acetate in severe hyponatremia in the intensive care unit. Clin J Am Soc Nephrol. 2014;9:229–37. https://doi.org/10.2215/CJN.00950113.
Perianayagam A, Sterns RH, Silver SM, Grieff M, Mayo R, Hix J, et al. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol. 2008;3:331–6. https://doi.org/10.2215/CJN.03190807.
Soupart A, Ngassa M, Decaux G. Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia. Clin Nephrol. 1999;51:383–6.
Oya S, Tsutsumi K, Ueki K, Kirino T. Reinduction of hyponatremia to treat central pontine myelinolysis. Neurology. 2001;57:1931–2.
Saner FH, Koeppen S, Meyer M, Kohnle M, Herget-Rosenthal S, Sotiropoulos GC, et al. Treatment of central pontine myelinolysis with plasmapheresis and immunoglobulins in liver transplant patient. Transpl Int. 2008;21:390–1. https://doi.org/10.1111/j.1432-2277.2007.00608.x.
Butterworth RF. Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure. J Clin Exp Hepatol. 2015;5:S96–S103. https://doi.org/10.1016/j.jceh.2014.02.004.
Wendon J, Cordoba J, Dhawan A, Larsen FS, Manns M, Nevens F, et al. EASL 2017 clinical practice guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66:1047–81. https://doi.org/10.1016/j.jhep.2016.12.003.
Lai A, Zeller M, Millen T, Kavsak P, Lamontagne F, Cook D, et al. Chloride concentration of commonly available 5% human albumin solutions. In: Paper presented at the Society of Critical Care Medicine 46th Critical Care Congress, Honolulu, 2016.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Henke, V.G., Bokoch, M.P., Liu, L.L. (2019). Management of Hyponatremia in End-Stage Liver Disease. In: Bezinover, D., Saner, F. (eds) Critical Care for Potential Liver Transplant Candidates. Springer, Cham. https://doi.org/10.1007/978-3-319-92934-7_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-92934-7_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-92933-0
Online ISBN: 978-3-319-92934-7
eBook Packages: MedicineMedicine (R0)